A Phase 1, Pharmacokinetic and Pharmacodynamic Study of AR882 in Adult Volunteers With Various Degrees of Renal Impairment
Latest Information Update: 10 Aug 2022
At a glance
- Drugs AR 882 (Primary)
- Indications Gout; Hyperuricaemia
- Focus Pharmacokinetics
- Sponsors Arthrosi Therapeutics
- 18 Jul 2022 Status changed from recruiting to completed.
- 08 Nov 2021 Planned End Date changed from 1 Sep 2021 to 1 Jul 2022.
- 08 Nov 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Jun 2022.